Company Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFβ) superfamily has enabled the development of a proprietary platform.
This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.
The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD).
Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFβ1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies.
The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFβ1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias.
Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2012 |
| IPO Date | May 24, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 289 |
| CEO | David Hallal |
Contact Details
Address: 301 Binney Street, 3rd Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 857 259 3860 |
| Website | scholarrock.com |
Stock Details
| Ticker Symbol | SRRK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001727196 |
| CUSIP Number | 80706P103 |
| ISIN Number | US80706P1030 |
| Employer ID | 82-3750435 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David L. Hallal | Chief Executive Officer and Chairman of the Board |
| Mo Qatanani Ph.D. | Chief Scientific Officer |
| Dr. Akshay K. Vaishnaw M.D., Ph.D. | President of Research & Development, Member of Scientific Advisory Board and Director |
| Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Vikas Sinha C.A., CPA, M.B.A. | Chief Financial Officer |
| Robert Keith Woods | Chief Operating Officer |
| Erin Moore CPA | Interim Principal Financial and Accounting Officer |
| Rushmie Nofsinger | Vice President of Corporate Affairs and Investor Relations |
| Junlin Ho J.D. | General Counsel and Corporate Secretary |
| Caryn Parlavecchio | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 3, 2026 | 8-K/A | [Amend] Current report |
| Mar 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2026 | 10-K | Annual Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 23, 2026 | 144 | Filing |
| Feb 10, 2026 | SCHEDULE 13G | Filing |
| Jan 22, 2026 | 144 | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 16, 2025 | 144 | Filing |